Abbott: FDA 510(k) clearances across all its applicant names
FDA lists 1,718 510(k) clearances, 120 PMA and 5 De Novo decisions across the 67 applicant names Caduvo groups under Abbott, first 1976, latest 2026. Median 510(k) review time across these names: 70 days. Since 2017 the median was 112 days, against 134 days for all cleared 510(k)s in the same product codes. Groups are curated by Caduvo from public sources listed below; FDA does not group applicants. Counts include filings made before an acquisition, and can include older filings by a business that was later sold when FDA records them under the same applicant name; see the notes on this page.
510(k) clearances per year
| Year | Clearances | Median review days |
|---|---|---|
| 2012 | 29 | 89 |
| 2013 | 25 | 108 |
| 2014 | 20 | 127 |
| 2015 | 24 | 48 |
| 2016 | 23 | 111 |
| 2017 | 19 | 93 |
| 2018 | 15 | 56 |
| 2019 | 17 | 58 |
| 2020 | 18 | 93 |
| 2021 | 14 | 112 |
| 2022 | 29 | 150 |
| 2023 | 33 | 126 |
| 2024 | 16 | 130 |
| 2025 | 29 | 127 |
| 2026 | 15 | 88 |
The 67 FDA applicant names in this group
| Applicant name | 510(k) clearances | PMA | De Novo | Years |
|---|---|---|---|---|
| Abbott Laboratories | 890 | 30 | 0 | 1976–2026 |
| St Jude Medical | 128 | 11 | 0 | 1989–2018 |
| Advanced Cardiovascular Systems, Inc. | 103 | 1 | 0 | 1982–2002 |
| Pacesetter Systems | 96 | 2 | 0 | 1976–1991 |
| ABBOTT MEDICAL | 60 | 33 | 0 | 2019–2026 |
| Abbott Vascular | 50 | 14 | 0 | 2000–2022 |
| Biosite Incorporated | 45 | 0 | 1 | 1990–2010 |
| Abbott Diabetes Care, Inc. | 39 | 2 | 1 | 2000–2024 |
| Abbott Diagnostics | 28 | 0 | 0 | 1981–1997 |
| Abbott Point of Care, Inc. | 22 | 0 | 0 | 2011–2026 |
| I-Stat Corp. | 21 | 0 | 0 | 1989–2006 |
| Abbott Molecular, Inc. | 18 | 14 | 1 | 2008–2025 |
| Alere Scarborough, Inc. | 16 | 0 | 1 | 2012–2019 |
| Aga Medical Corp. | 16 | 0 | 0 | 2000–2012 |
| Medisense, Inc. | 15 | 0 | 0 | 1990–1999 |
| Abbott Mfg., Inc. | 14 | 0 | 0 | 1990–1998 |
| Abbott | 13 | 1 | 0 | 2018–2026 |
| Irvine Biomedical, Inc. | 11 | 2 | 0 | 1995–2008 |
| St. Jude Medical, Cardiac Rhythm Management Divisi | 10 | 2 | 0 | 2008–2012 |
| Thoratec Laboratories Corp. | 10 | 1 | 0 | 1978–2000 |
| Abbott Ireland Diagnostics Division | 8 | 0 | 0 | 2021–2023 |
| Pacesetter, Inc. | 8 | 0 | 0 | 1995–1998 |
| Abbott Diagnostics Scarborough, Inc. | 7 | 1 | 0 | 2019–2026 |
| Abbott Vascular-Cardiac Therapies | 6 | 1 | 0 | 2010–2011 |
| Abbott (St. Jude Medical) | 6 | 0 | 0 | 2019–2021 |
| Abbott Vascular-Vascular Solutions | 6 | 0 | 0 | 2008–2009 |
| Inverness Medical Innovations, Inc. | 6 | 0 | 0 | 2001–2007 |
| St. Jude Medical Systems AB | 5 | 0 | 0 | 2011–2014 |
| Abbott Electrophysiology | 4 | 0 | 0 | 2016–2017 |
| Abbott Laboratories Diagnostics Division | 4 | 0 | 0 | 2019–2024 |
| Alere Scarborough, Inc D/B/A Binax, Inc. | 4 | 0 | 0 | 2011–2014 |
| Evalve, Inc. | 4 | 0 | 0 | 2009–2010 |
| Thoratec Corporation | 3 | 1 | 0 | 2013–2015 |
| Alere Technologies AS | 3 | 0 | 0 | 2015–2018 |
| Abbott Vascular Devices | 2 | 2 | 0 | 2005–2005 |
| Abbott (Formerly Thoratec Corporation) | 2 | 0 | 0 | 2020–2022 |
| Abbott Ireland | 2 | 0 | 0 | 2025–2025 |
| Alere San Diego, Inc. | 2 | 0 | 0 | 2015–2023 |
| Medapps Inc., Dba Alere Connect | 2 | 0 | 0 | 2013–2013 |
| St. Jude Medical, Daig Division, Inc. | 2 | 0 | 0 | 2005–2005 |
| St. Jude Medical Neuromodulation | 2 | 0 | 0 | 2011–2013 |
| St. Jude Medical (Now Abbott Medical) | 2 | 0 | 0 | 2019–2019 |
| Irvine Biomedical,Inc.(Ibi) | 1 | 1 | 0 | 2007–2007 |
| Abbott Diagnostics Mfg., Inc. | 1 | 0 | 0 | 1999–1999 |
| Abbott Diagnostics Technologies AS | 1 | 0 | 0 | 2023–2023 |
| Abbott Laboratories (Perclose, Inc.) | 1 | 0 | 0 | 2005–2005 |
| Abbott Pont of Care, Inc. | 1 | 0 | 0 | 2011–2011 |
| Abbott Rapid Diagnostics | 1 | 0 | 0 | 2017–2017 |
| Aga Medical COrporation (Wholly Owned by St. Jude Medical CO | 1 | 0 | 0 | 2016–2016 |
| Aga Medical Corporation (Wholly Owned by St.Jude Medical Cor | 1 | 0 | 0 | 2016–2016 |
| Alere, San Diego, Dba Biosite INcorporated, Dba IN | 1 | 0 | 0 | 2010–2010 |
| Alere San Diego Inc. Dba Biosite,Innovacon,Hemosen | 1 | 0 | 0 | 2013–2013 |
| Alere San Diego, Inc (Formally Biosite Incorporate | 1 | 0 | 0 | 2012–2012 |
| Inverness Medical, Inc. | 1 | 0 | 0 | 2010–2010 |
| Inverness Medical-Biostar, Inc. | 1 | 0 | 0 | 2006–2006 |
| Inverness Medical Professional Diagnostics | 1 | 0 | 0 | 2007–2007 |
| Irvine Biomedical, A St. Jude Medical Company | 1 | 0 | 0 | 2022–2022 |
| Irvine Biomedical, Inc., A St. Jude Medical Company | 1 | 0 | 0 | 2014–2014 |
| St. Jude Medical Cardiovascular Group, Inc. | 1 | 0 | 0 | 2001–2001 |
| St Jude Medical, Crmd | 1 | 0 | 0 | 2010–2010 |
| St. Jude Medical, Inc.-Endocardial Solutions | 1 | 0 | 0 | 2006–2006 |
| St. Jude Medical, Mediguide Navigation Systems | 1 | 0 | 0 | 2012–2012 |
| St. Jude Medical (Now Part of Abbott Medical) | 1 | 0 | 0 | 2018–2018 |
| St. Jude Medical (Now Part of the Abbott Medical) | 1 | 0 | 0 | 2017–2017 |
| Thoratec Corporation (Now Part of Abbott) | 1 | 0 | 0 | 2019–2019 |
| Abbott Vascular (Idef Technologies Inc) | 0 | 1 | 0 | — |
| Inverness Medical Professional Diagnostics-Binax | 0 | 0 | 1 | — |
Review time against the same product codes
Since 2017, 510(k)s cleared under these names took a median 112 days from FDA receipt to decision. All cleared 510(k)s in the same product codes over the same years took a median 134 days.
Top product codes
| Product code | Device | Submissions | 510(k) clearances |
|---|---|---|---|
| FRN | Pump, Infusion | 76 | 76 |
| DQX | Wire, Guide, Catheter | 75 | 75 |
| DQY | Catheter, Percutaneous | 67 | 67 |
| DQK | Computer, Diagnostic, Programmable | 48 | 48 |
| DTB | Permanent Pacemaker Electrode | 40 | 39 |
| DYB | Introducer, Catheter | 40 | 40 |
| DXY | Implantable Pacemaker Pulse-Generator | 32 | 28 |
| FPA | Set, Administration, Intravascular | 32 | 32 |
| NBW | System, Test, Blood Glucose, Over The Counter | 32 | 32 |
| GKZ | Counter, Differential Cell | 30 | 30 |
Plus 444 more product codes.
Review panels
- Cardiovascular (612)
- Clinical Chemistry (495)
- General Hospital (163)
- Microbiology (159)
- Clinical Toxicology (159)
- Hematology (80)
- Gastroenterology and Urology (56)
- Immunology (50)
- General and Plastic Surgery (17)
- Neurology (16)
- Anesthesiology (15)
- Pathology (8)
- Radiology (3)
- Medical Genetics (1)
- Obstetrics and Gynecology (1)
Most recent Abbott 510(k) clearances
| 510(k) | Device | Applicant name | Product code | Decision date | Review days |
|---|---|---|---|---|---|
| K262156 | Anti-HCV Next | Abbott Laboratories | MZO | 2026-09-23 | 89 |
| K261729 | EnSite X EP System | ABBOTT MEDICAL | DQK | 2026-09-17 | 114 |
| K262747 | ID NOW Influenza A & B 2; ID NOW RSV; ID NOW Strep A 2; ID NOW COVID-19 2.0 | Abbott Diagnostics Scarborough, Inc. | OCC | 2026-08-31 | 28 |
| K262006 | EnSite X EP System | ABBOTT MEDICAL | DQK | 2026-07-15 | 30 |
| K261825 | Amplatzer TorqVue LP Delivery System; Amplatzer TorqVue LP Catheter | Abbott | DQY | 2026-07-02 | 30 |
| K261039 | i-STAT Crea cartridge with the i-STAT 1 System | Abbott Point of Care, Inc. | CGL | 2026-06-26 | 88 |
| K261631 | Amplatzer TorqVue Exchange System | ABBOTT MEDICAL | DQY | 2026-06-17 | 30 |
| K253051 | i-STAT hs-TnI cartridge with the i-STAT Alinity System | Abbott Point of Care, Inc. | MMI | 2026-06-11 | 262 |
| K252424 | Anti-HCV Next | Abbott Laboratories | MZO | 2026-04-28 | 270 |
| K260993 | Amplatzer TorqVue Delivery System | Abbott | DQY | 2026-04-24 | 29 |
1,708 earlier clearances. See the full list in Caduvo.
PMA and De Novo decisions
| Number | Pathway | Device | Decision date |
|---|---|---|---|
| P260019 | PMA | Amplatzer Paraclose PVL Occluder | 2026-10-27 |
| DEN250049 | De Novo | Integrated Continuous Glucose Ketone Monitoring System | 2026-08-25 |
| P250022 | PMA | Volt PFA System | 2025-12-19 |
| P240042 | PMA | Tendyne Transcatheter Mitral Valve System | 2025-05-23 |
| P230036 | PMA | Esprit BTK Everolimus Eluting Resorbable Scaffold System | 2024-04-26 |
Recalls
876 product recalls in 456 recall events under these names; 164 initiated in the last five years.
369 product recalls in 169 recall events filed under other recalling-firm names cite a 510(k) or PMA held under these applicant names; 31 initiated in the last five years. Most often: Hospira Inc. (118), Abbott Laboratories HPD/ADD/GPRD (37), Hospira Inc (31).
These recall records list the clearance number, so the device was cleared under this name. The recalling firm may be the same company under another spelling, a company that acquired the product line, a relabeler or a contract manufacturer. They are not added to the count above.
Recalling firms are matched to the applicant names above by name only, so recalls filed under other names are not counted. A recall count says nothing about how safe one company's devices are compared with another's.
Device clinical trials
ClinicalTrials.gov lists 45 device studies (5 active or recruiting) with an industry lead sponsor under the 3 sponsor names below. Most recent:
- NCT07739342: Evaluating the Occurrence of DKA in People With Type I Diabetes (Abbott Diabetes Care; Not yet recruiting, started 2026-09)
- NCT06921902: Glycemic Metrics and Patterns in People With and Without Prediabetes (Abbott Diabetes Care; Recruiting, started 2025-02-28)
- NCT06668935: Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring (Abbott Diabetes Care; Recruiting, started 2024-10-24)
- NCT06268808: Initiation of Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin, in Italy (Abbott Diabetes Care; Completed, started 2024-07-19)
- NCT06295835: Method Comparison Study for Measuring Potassium (K) and Ionized Calcium (iCa) in Blood (Abbott Point of Care; Completed, started 2024-05-31)
| Lead sponsor name on ClinicalTrials.gov | Device studies |
|---|---|
| Abbott Diabetes Care | 42 |
| Abbott Point of Care | 2 |
| Abbott | 1 |
Sponsor names are matched to the applicant names above by name, with punctuation and legal suffixes removed, plus sponsor names reviewed for this group. Studies listed under other sponsor names are not counted.
Parent company SEC filings
ABBOTT LABORATORIES (ABT): EDGAR filings, CIK 1800. The parent's SEC registrant is entered by hand for this group, not matched by name.
How this group is built
Groups are curated by Caduvo from public sources listed below; FDA does not group applicants. Counts include filings made before an acquisition, and can include older filings by a business that was later sold when FDA records them under the same applicant name; see the notes on this page.
St. Jude Medical (January 2017; brought Pacesetter, AGA Medical, Thoratec), Alere (October 2017; brought Biosite and Inverness Medical), Advanced Cardiovascular Systems (Guidant vascular, 2006), i-STAT (2004), TheraSense (2004), MediSense (1996), Evalve (2009), Cardiovascular Systems Inc (2023). Includes filings made before each acquisition. Left out: Abbott Medical Optics (sold to Johnson & Johnson 2017), ALERE (a 1984 filer predating Alere Inc), AGA MEDICAL PRODUCTS (1992–1993, predates AGA Medical), Abbott Spine (sold to Zimmer 2008), AbbVie (pharma spin-off 2013). The generic CARDIOVASCULAR SYSTEMS names are left out because not every filing could be confirmed as the company acquired in 2023.
Sources
- https://en.wikipedia.org/wiki/Abbott_Laboratories
- https://en.wikipedia.org/wiki/St._Jude_Medical
- https://en.wikipedia.org/wiki/Alere
- https://en.wikipedia.org/wiki/Thoratec
Frequently asked questions
How many FDA 510(k) clearances are listed across Abbott's applicant names?
FDA lists 1,718 510(k) clearances, 120 PMA and 5 De Novo decisions across the 67 applicant names Caduvo groups under Abbott, first 1976, latest 2026. FDA records each applicant name separately; Caduvo adds up the names listed on this page.
Which FDA applicant names does Abbott file under?
The names with the most 510(k) clearances in this group are Abbott Laboratories (890); St Jude Medical (128); Advanced Cardiovascular Systems, Inc. (103); Pacesetter Systems (96); ABBOTT MEDICAL (60). The full list of 67 names is on this page.
How long does FDA take to clear Abbott 510(k)s?
The median time from FDA receipt to decision across 510(k)s cleared under these names is 70 days. Since 2017 the median was 112 days, against 134 days for all cleared 510(k)s in the same product codes.
Does the Abbott count include acquired companies?
Yes. A group includes filings an acquired business made under its own name, including before the acquisition. Businesses that were sold are left out, and names whose ownership is unclear are not included. FDA does not group applicants; the sources for each grouping are listed on this page.
How many device clinical trials does Abbott sponsor?
ClinicalTrials.gov lists 45 device studies (5 active or recruiting) with an industry lead sponsor under 3 sponsor names Caduvo groups under Abbott. ClinicalTrials.gov names the sponsor on each study; Caduvo adds up the names listed on this page.
Next steps
- See all 1,718 Abbott clearances with predicates and recalls
- Run predicate analysis for product code FRN, Abbott's most frequent
Compiled by Caduvo from public U.S. government records. Counts cover filings under the applicant names shown on this page only. Review days run from FDA receipt to decision. Not reviewed or endorsed by FDA or any other agency, or by the companies named. Not regulatory advice. Report an error in this grouping or data. Data and corrections policy.
All parent companies · FDA device companies by applicant name · FDA product code lookup